1[1]Laupacis A,Albers G,Dalen J E,et al .Antithrombotic therapy in atrial fibrillation.Chest,1995,108:352s～359s
2[2]Atrial Fibrillation Investigators.Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation:analysis of pooled data from five randomized controlled trials.Arch Intern Med,1994,154:1449～1457
3[3]Vemmos K N,Takis CE,Georgilis K,et al .the Athens stroke registry:results of a five-year hospital-based study.Cerebrovasc Dis,2000,10:133～41
5[5]Falk RH,Podrid PJ.Atrial fibrillation mechanisms and management. 2nd edition Maple Press, 1997.277～98
6[6]Antithrombotic Therapy in Atrial Fibrillation\.The cardiopulmonary and critical care journal.1998,114(5,sup):579s～590s
7[7]Koudstaal PJ.Antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks .Cochrane Database Syst Rev,2000,(2): 186～190
8[8]Yamaguchi T.Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation-a multicenter,prospective,randomized trial .Stroke,2000,31:817～21
9[9]Gallus AS,Baker RI,Chong BH,et al.Consensus guidelines for warfarin therapy-recommendations from the Australian Society of Thrombosis and Haemostasis .MJA,2000,172:600～5
10[10]Hylek EM,Skates SJ,Sheehan MA,et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with non-rheumatic atrial fibrillation.N Engl Med J,1996,335:540～6
